Quarterly Result21 Sept 2026, 07:11 pm
Symbiotec Pharmalab approves Q1 FY27 unaudited financial results
AI Summary
Symbiotec Pharmalab Ltd's Board of Directors met on September 21, 2026, and approved the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company has enclosed the unaudited financial results along with the Limited Review Reports. The trading window for dealing in the company's securities will remain closed until 48 hours after this announcement. The filing also includes the Independent Auditor's Review Report on the quarterly unaudited consolidated financial results.
Key Highlights
- Board approved unaudited Standalone & Consolidated Financial Results.
- Results are for the quarter ended June 30, 2026 (Q1 FY27).
- Limited Review Reports are enclosed with the results.
- Trading window closed for 48 hours post-announcement.
- Independent Auditor's Review Report is included.
Price Impact
More from SYMBIOTEC